Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Investments: 2021

Historic Long-Term Investments for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2021 value amounting to $64.8 million.

  • ARS Pharmaceuticals' Long-Term Investments was N/A to $24.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $24.2 million, marking a year-over-year change of. This contributed to the annual value of $64.8 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Long-Term Investments of $64.8 million as of FY2021.
  • In the past 5 years, ARS Pharmaceuticals' Long-Term Investments registered a high of $64.8 million during FY2021, and its lowest value of $64.8 million during FY2021.
  • For the 1-year period, ARS Pharmaceuticals' Long-Term Investments averaged around $64.8 million, with its median value being $64.8 million (2021).